Published in Oncoimmunology on October 29, 2015
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109
Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies | NCT02061761
Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch (2017) 0.75
Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature (2014) 4.88
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood (2011) 2.47
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol (2008) 1.50
TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer (2003) 1.10
Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma. Cancer Res (2015) 1.06
TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer (2004) 0.89
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T- Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Res (2015) 0.88
Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J Cancer (2014) 0.87